A nurse has warned about a common Mounjaro ‘mistake’ that can increase people’s risk of deadly organ damage.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised ...

A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...